EU regulators may fine Ranbaxy

June 04, 2013 01:14 pm | Updated November 16, 2021 11:56 pm IST - New Delhi

Reports from Brussels suggest that European Union anti-trust regulators may fine Ranbaxy for allegedly blocking of entry of cheaper generic medicines in the market.

Reports said that the domestic pharmaceutical company was among the nine companies that are to be fined for the allegedly blocking the entry of the generic medicines in the EU.

When contacted, a Ranbaxy spokesperson said: “We will not like to offer any comments at this point.”

The reports also named Denmark’s Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.